Volume 73, Issue 11, Pages (June 2008)

Slides:



Advertisements
Similar presentations
Volume 54, Pages S135-S139 (December 1998)
Advertisements

Volume 82, Issue 12, Pages (December 2012)
Systemic Implementation Strategies to Improve Hypertension: The Kaiser Permanente Southern California Experience  John J. Sim, MD, Joel Handler, MD, Steven.
Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies  Richard.
Chronic Kidney Disease in Diabetes
Volume 55, Issue 2, Pages (February 1999)
From secondary to primary prevention of progressive renal disease: The case for screening for albuminuria  Paul E. De Jong, Barry M. Brenner  Kidney International 
Biomarkers in kidney fibrosis: are they useful?
Volume 79, Issue 12, Pages (June 2011)
Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes  Robert W. Schrier, Raymond.
Gudrun Hatlen, Solfrid Romundstad, Stein I. Hallan 
Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets  David M. Spiegel, Kate Brady  Kidney.
Mycophenolate mofetil treatment for primary glomerular diseases
Volume 93, Issue 1, Pages (January 2018)
Volume 86, Issue 3, Pages (September 2014)
Chronic Kidney Disease in Diabetes
Prehypertension and chronic kidney disease: the ox or the plow?
Peter Rossing, Philip Hougaard, Hans-Henrik Parving 
Volume 88, Issue 2, Pages (August 2015)
Volume 82, Issue 12, Pages (December 2012)
Volume 77, Issue 8, Pages (April 2010)
Volume 90, Issue 3, Pages (September 2016)
Volume 55, Issue 2, Pages (February 1999)
Volume 79, Issue 12, Pages (June 2011)
Volume 77, Issue 1, Pages 5-6 (January 2010)
How to interpret the eGFR in patients with small body surface area
Volume 76, Issue 3, Pages (August 2009)
Volume 54, Issue 4, Pages (October 1998)
Volume 74, Issue 3, Pages (August 2008)
Volume 81, Issue 3, Pages (February 2012)
Long-term study of mycophenolate mofetil treatment in IgA nephropathy
U-shaped effect of eGFR and mortality
Volume 76, Issue 6, Pages (September 2009)
Blood pressure targets in hemodialysis patients
Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation?  Pantelis A. Sarafidis, Luis.
Volume 81, Issue 6, Pages (March 2012)
Volume 85, Issue 3, Pages (March 2014)
Volume 81, Issue 6, Pages (March 2012)
Volume 82, Issue 7, Pages (October 2012)
Volume 69, Issue 12, Pages (June 2006)
Proteinuria and hypertensive nephrosclerosis in African Americans
Methods for guideline development
Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes  J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.
Volume 87, Issue 1, Pages (January 2015)
The kidney, a cardiovascular risk marker, and a new target for therapy
Volume 78, Issue 5, Pages (September 2010)
Nephrology Crossword: Glomerulonephritis
Volume 85, Issue 5, Pages (May 2014)
Volume 54, Pages S135-S139 (December 1998)
Volume 73, Issue 8, Pages (April 2008)
Volume 58, Issue 3, Pages (September 2000)
Volume 80, Issue 3, Pages (August 2011)
Douglas G Matsell, Colin T White  Kidney International 
Volume 58, Issue 5, Pages (November 2000)
Volume 77, Issue 12, Pages (June 2010)
The course of the remnant kidney model in mice
Volume 95, Issue 6, Pages (June 2019)
Volume 80, Issue 10, Pages (November 2011)
Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension  Julian Segura, Carlos Campo, Luis M. Ruilope  Kidney.
Volume 72, Issue 7, Pages (October 2007)
Volume 75, Issue 1, Pages (January 2009)
Importance of blood pressure control in hemodialysis patient survival
Volume 82, Issue 9, Pages (November 2012)
Adiponectin: good, bad, or just plain ugly?
Volume 81, Issue 11, Pages (June 2012)
Atrasentan reduces albuminuria in diabetic apoE KO mice.
Friends, social networks, and progressive chronic kidney disease
National Kidney Foundation's Kidney Early Evaluation Program (KEEP) Annual Data Report 2009: Executive Summary  Peter A. McCullough, MD, MPH, Joseph A.
Antonio Piccoli, Luana Pillon  Kidney International 
Volume 86, Issue 2, Pages (August 2014)
Presentation transcript:

Volume 73, Issue 11, Pages 1303-1309 (June 2008) Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study  G.L. Bakris, R.D. Toto, P.A. McCullough, R. Rocha, D. Purkayastha, P. Davis  Kidney International  Volume 73, Issue 11, Pages 1303-1309 (June 2008) DOI: 10.1038/ki.2008.102 Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 1 Patient disposition. Kidney International 2008 73, 1303-1309DOI: (10.1038/ki.2008.102) Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 2 Median percent change in the urinary albumin-to-creatinine (Ualb:Cr) ratio from baseline at week 52 (LOCF) for the entire intent-to-treat cohort. Note: Baseline data was available for 148 patients in the benazepril/amlodipine group and 146 patients in the benazepril/HCTZ group. At the end of the study (week 52, last observation carried forward; LOCF) data were available for only 145 patients in each group. HCTZ, hydrochlorothiazide. Kidney International 2008 73, 1303-1309DOI: (10.1038/ki.2008.102) Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 3 Mean change in sitting systolic and diastolic blood pressure from baseline at Week 52 by treatment group. SBP, systolic blood pressure; DBP, diastolic blood pressure. Kidney International 2008 73, 1303-1309DOI: (10.1038/ki.2008.102) Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 4 Proportion of patients with microalbuminuria only who attained normalization of the urinary albumin-to-creatinine (Ualb:Cr) ratio (<30 mg g−1) by the end of the study (intent-to-treat population). Baseline data were available for 148 patients in the benazepril/amlodpine group and 146 patients in the benazepril/HCTZ group. The data shown exclude patients who had a baseline Ualb:Cr ratio of <30 mg g−1 (benazepril/amlodipine: 33 patients and benazepril/HCTZ 13 patients). Kidney International 2008 73, 1303-1309DOI: (10.1038/ki.2008.102) Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 5 Mean change in estimated glomerular filtration rate (eGFR) from baseline to end of study. Baseline data were available for 153 patients in the benazepril/amlodipine group and 150 patients in the benazepril/HCTZ group. End of the study (week 52, LOCF) data were available for all patients with a baseline measurement. Kidney International 2008 73, 1303-1309DOI: (10.1038/ki.2008.102) Copyright © 2008 International Society of Nephrology Terms and Conditions